Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACXP Acurx Pharmaceuticals, LLC*

Post-Mkt 05-06 18:50:03 EDT

2.09

+0.09

+4.50%

盘后2.12

+0.03+1.44%

18:33 EDT

High2.14	Low2.04	Vol69.67K
Open2.12	D1 Closing2.00	Amplitude4.83%
Mkt Cap7.67M	Tradable Cap7.42M	Total Shares3.67M
T/O146.43K	T/O Rate1.96%	Tradable Shares3.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACXP","market":"US","secType":"STK","nameCN":"Acurx Pharmaceuticals, LLC*","latestPrice":2.09,"timestamp":1778097600000,"preClose":2,"halted":0,"volume":69666,"hourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.09,"latestTime":"18:33 EDT","volume":1485,"amount":3083.8463370000004,"timestamp":1778106792424,"change":0.03,"changeRate":0.014354,"amplitude":0.028708},"delay":0,"changeRate":0.04499999999999993,"floatShares":3551500,"shares":3671093,"eps":-5.32,"marketStatus":"Post-Mkt","change":0.09,"latestTime":"05-06 18:50:03 EDT","open":2.12,"high":2.1367,"low":2.0401,"amount":146428.318092,"amplitude":0.0483,"askPrice":2.12,"askSize":307,"bidPrice":2,"bidSize":4001,"shortable":3,"etf":0,"ttmEps":-5.32,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778112000000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":2,"preHourTrading":{"tag":"盘前","latestPrice":2.11,"preClose":2,"latestTime":"09:29 EDT","volume":3178,"amount":6591.3550528000005,"timestamp":1778074199999,"change":0.11,"changeRate":0.055,"amplitude":0.065},"postHourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.09,"latestTime":"18:33 EDT","volume":1485,"amount":3083.8463370000004,"timestamp":1778106792424,"change":0.03,"changeRate":0.014354,"amplitude":0.028708},"volumeRatio":0.503408,"impliedVol":1.1448,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/ACXP/","defaultTab":"news","newsList":[{"id":"2632434958","title":"Acurx DNA pol IIIC inhibitors spare gut microbiome in MRSA mouse study, poster shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2632434958","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632434958?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:01","pubTimestamp":1777896105,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals announced microbiome data on its preclinical DNA pol IIIC inhibitor antibiotics were presented in a scientific poster at ESCMID Global 2026 in Munich, held April 17-21.In a mouse MRSA infection model, the compounds showed systemic antibacterial activity while preserving gut microbiome diversity and baseline-like community structure, contrasting with linezolid.The results support a potential class effect that could differentiate the program by aiming to treat serious Gram-positive infections while reducing risk of antibiotic-driven dysbiosis.Acurx said its DNA pol IIIC inhibitor candidates are positioned for FDA QIDP and Fast-Track eligibility, signaling a regulatory pathway aimed at accelerating development for high-need infections.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL923BSh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","ACXP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516945","title":"Acurx CEO to join Alliance Global Partners Healthcare Company Showcase fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516945","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516945?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:00","pubTimestamp":1777464045,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals CEO David P. Luci set to join a virtual fireside chat at Alliance Global Partners Healthcare Company Showcase on May 24, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL1wF8W8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628740208","title":"BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2628740208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628740208?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:01","pubTimestamp":1776686511,"startTime":"0","endTime":"0","summary":"BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business UpdateAcurx Pharmaceuticals Inc ACXP.O:ACURX PHARMACEUTICALS TO DISCUSS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA5F0XWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","ACXP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628740919","title":"Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2628740919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628740919?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:00","pubTimestamp":1776686411,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA5F0XWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACXP","BK4539","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628241877","title":"BRIEF-Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2628241877","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628241877?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:44","pubTimestamp":1776372244,"startTime":"0","endTime":"0","summary":"BRIEF-Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 16 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O:ACURX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA2PBQWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACXP","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627219023","title":"Acurx announces $7.1M registered direct offering priced at-the-market","url":"https://stock-news.laohu8.com/highlight/detail?id=2627219023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627219023?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:19","pubTimestamp":1776349185,"startTime":"0","endTime":"0","summary":"Acurx (ACXP) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acurx-announces-7-1m-registered-direct-offering-priced-at-the-market-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acurx-announces-7-1m-registered-direct-offering-priced-at-the-market-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACXP","BK4139","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627029053","title":"Acurx prices $2.5 million registered direct offering at $3.03 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627029053","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627029053?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:01","pubTimestamp":1776340895,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals launched registered direct offering of 825,085 common shares or pre-funded warrants at USD 3.03 per share.Deal expected to raise about USD 2.5 million in gross proceeds.Concurrent private placement includes short-term warrants for up to 1,650,170 shares at USD 2.78 exercise price.Closing expected on or about April 16, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLb8F38Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACXP","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627290611","title":"Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2627290611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627290611?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:00","pubTimestamp":1776340801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA2PWLG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","BK4539","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625568589","title":"New to The Street announce re-signing of Acurx Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2625568589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625568589?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:33","pubTimestamp":1775568801,"startTime":"0","endTime":"0","summary":"New to The Street announces the re-signing of Acurx (ACXP) Pharmaceuticals. The renewed agreement extends a multi-year strategic media partnership ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/new-to-the-street-announce-re-signing-of-acurx-pharmaceuticals-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/new-to-the-street-announce-re-signing-of-acurx-pharmaceuticals-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","ACXP","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623031113","title":"Acurx wins Korean patent for DNA Polymerase IIIC inhibitor antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2623031113","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623031113?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:05","pubTimestamp":1774868746,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals reported Korean Intellectual Property Office grant of new patent covering DNA Polymerase IIIC inhibitors, including compositions of matter, methods of use, pharmaceutical compositions.Patent strengthens intellectual property coverage for ACX-375C program targeting DNA Polymerase IIIC.Acurx said it now holds four U.S. patents, with additional granted patents in Israel, Japan, India, Australia, Korea.Ibezapolstat described as ready to move into international Phase 3 registration trials in US, EU for oral treatment of acute C. difficile infection.Company also plans clinical trial of ibezapolstat in multiply recurrent C. difficile infection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL36Htf1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4539","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069667","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069667","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069667?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:16","pubTimestamp":1774350967,"startTime":"0","endTime":"0","summary":"Netgear  shares were 12% higher pre-bell Tuesday after the Federal Communications Commission banned the import of all new foreign-made consumer routers.Jefferies Financial  stock was up 8% following a Financial Times report that Sumitomo Mitsui Financial Group  is considering acquiring the US-based investment bank.Sol-Gel Technologies  shares were 7% higher, a day after the company said it has priced an oversubscribed underwritten offering of ordinary shares for gross proceeds of about $33.1 million.Acurx Pharmaceuticals  stock was up 6%, reversing from Monday's slide.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4207","BK4563","BK4127","JEF","SMFG","BK4539","ACXP","NTGR","BK4559","BK4007","SLGL","BK4020","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619812269","title":"Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619812269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619812269?lang=en_us&edition=fundamental","pubTime":"2026-03-14 23:50","pubTimestamp":1773503409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvalent (NUVL – Research Report) and Acurx Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-nuvalent-nuvl-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-nuvalent-nuvl-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSG","BK4139","ACXP","LU0029874061.USD","BK4563","BK4588","XBI","BLSX","BK4539","BK4581","LABU","BK4112","BK4585","NUVL","BK4137","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619114413","title":"Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114413","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114413?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:35","pubTimestamp":1773423336,"startTime":"0","endTime":"0","summary":"In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Acurx Pharmaceuticals, with a price target of $10...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acurx-pharmaceuticals-acxp-gets-a-buy-from-alliance-global-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acurx-pharmaceuticals-acxp-gets-a-buy-from-alliance-global-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619112281","title":"Acurx price target lowered to $10 from $20 at Alliance Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112281?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:50","pubTimestamp":1773420620,"startTime":"0","endTime":"0","summary":"Alliance Global lowered the firm’s price target on Acurx (ACXP) to $10 from $20 and keeps a Buy rating on the shares following the Q4 report. The f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acurx-price-target-lowered-to-10-from-20-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acurx-price-target-lowered-to-10-from-20-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","ACXP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619190717","title":"Acurx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2619190717","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619190717?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:31","pubTimestamp":1773408706,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryAcurx Pharmaceuticals Inc ACXP.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N4011BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619199970","title":"Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619199970","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619199970?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:10","pubTimestamp":1773400205,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewUS biopharmaceutical firm's Q4 net loss narrowed as R&D and G&A expenses declinedCompany ended Q4 with $7.6 mln cash, up from $3.7 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL1N4010F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4539","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619199801","title":"Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2619199801","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619199801?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:01","pubTimestamp":1773399718,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.65) by 55.62 percent. This is a 78.53 percent increase over losses of $(3.40) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51236175/acurx-pharmaceuticals-q4-eps-0-73-beats-1-65-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4563","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619199383","title":"Acurx Pharmaceuticals Q4 EPS USD -0.73","url":"https://stock-news.laohu8.com/highlight/detail?id=2619199383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619199383?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:01","pubTimestamp":1773399660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nPLX132728:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4563","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619365199","title":"Press Release: Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619365199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619365199?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:01","pubTimestamp":1773399660,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025.Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:. -- In October 2025, the Company received gross proceeds from the exercise of. 170,068 Series F Warrants of approximately $1.4 million.-- Also in October 2025, we were one of five companies to make a formal. presentation at IDWeek in Atlanta at the session entitled New. Antimicrobials in the Pipeline. Presenting on behalf of Acurx were Dr.Michael Silverman, our Medical Director, and Dr. Kevin Garey, Professor. and Chair, University of Houston College of Pharmacy and the Principal. Investigator for microbiology and microbiome aspects of the ibezapolstat. clinical tri","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4215","MAA","BK4139","ACXP","BK4585","R","BK4539","BK4022","LABU","BK4588","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619193658","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193658","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619193658?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:00","pubTimestamp":1773396000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·KE Hldgs ADR                                    4Q       .11    6:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBUS","CAAP","CELC","ACXP","BETR","BZ","AEBI","CREX","CDNL","AVR","DERM","DCGO","ZTO","ETON","ACN","ESLT","DLO","FIVE","BIOA","AVAH","DOCU","ABEO","ASO","BRAG","CTMX","ASRT","ALVO","BEKE","BGSI","FDX","DLTR","ATAT","CAL","AGEN","ANDG","DRIO","ECOR","ELDN","CNTY","FLD","BDTX","ERAS","ARCO","DRI","BTM","CSIQ","EVEX","EQPT","ARX"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.acurxpharma.com","stockEarnings":[{"period":"1week","weight":-0.0291},{"period":"1month","weight":-0.4565},{"period":"3month","weight":-0.0476},{"period":"6month","weight":-0.6},{"period":"1year","weight":-0.7437},{"period":"ytd","weight":-0.1968}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.08634},{"month":2,"riseRate":0,"avgChangeRate":-0.144545},{"month":3,"riseRate":0.4,"avgChangeRate":0.164663},{"month":4,"riseRate":0.4,"avgChangeRate":-0.083182},{"month":5,"riseRate":0.4,"avgChangeRate":-0.054295},{"month":6,"riseRate":0.5,"avgChangeRate":0.118659},{"month":7,"riseRate":0,"avgChangeRate":-0.160175},{"month":8,"riseRate":0.2,"avgChangeRate":-0.087422},{"month":9,"riseRate":0,"avgChangeRate":-0.115354},{"month":10,"riseRate":0.6,"avgChangeRate":0.545147},{"month":11,"riseRate":0.2,"avgChangeRate":-0.181708},{"month":12,"riseRate":0.4,"avgChangeRate":-0.094208}],"exchange":"NASDAQ","name":"Acurx Pharmaceuticals, LLC*","nameEN":"Acurx Pharmaceuticals, LLC*"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acurx Pharmaceuticals, LLC*,ACXP,Acurx Pharmaceuticals, LLC*股票,Acurx Pharmaceuticals, LLC*股票老虎,Acurx Pharmaceuticals, LLC*股票老虎国际,Acurx Pharmaceuticals, LLC*行情,Acurx Pharmaceuticals, LLC*股票行情,Acurx Pharmaceuticals, LLC*股价,Acurx Pharmaceuticals, LLC*股市,Acurx Pharmaceuticals, LLC*股票价格,Acurx Pharmaceuticals, LLC*股票交易,Acurx Pharmaceuticals, LLC*股票购买,Acurx Pharmaceuticals, LLC*股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction